Mylan N.V. and Biocon Ltd. announced that the European Medicines Agency accepted a Marketing Authorization Application for Pegfilgrastim, a proposed biosimilar for the reduction of the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy, with the exception of chronic myeloid leukaemia and myelodysplastic syndromes. In...
After Karen Knudsen departed from the American Cancer Society late last year, the question of where she will end up becoming the fodder for cocktail party chatter throughout oncology.
